Chemical Property of Wln: GA N-O3*3
Chemical Property:
- Melting Point:110°C (dec.)
- Boiling Point:83°Cat760mmHg
- Flash Point:°C
- PSA：206.64000
- Density:1.623g/cm3
- LogP:0.80900
- Water Solubility.:It is soluble in water.
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:0
- Exact Mass:131.92122
- Heavy Atom Count:5
- Complexity:24.8
- Purity/Quality:
-
98% *data from raw suppliers
GALLIUM NITRATE 95.00% *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- Statements:
8-36/37/38
- Safety Statements:
17-26-36/37/39
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:[N+](=O)(O)[O-].[Ga]
-
Description
Gallium nitrate, initially developed as an anticancer agent, was introduced by Fujisawa
as an orphan drug for the treatment of cancer-related hypercalcemia and bone
metastases that do not respond to adequate hydration. The compound acts specifically
on bone by inhibiting calcium resorption and also possibly by stimulating bone
formation. Compared with calcitonin and etidronate, gallium nitrate is more potent and
substantially longer acting. Other potential uses could be in the treatment of
osteoporosis and Paget’s disease.
-
Uses
Gallium is the second metal ion with clinical activity used in
cancer treatment. Gallium nitrate has demonstrated
antitumor activity in a variety of murine tumor models,
including Walker 256 carcinosarcoma, fibrosarcoma M-89,
leukemia K-1964, adenocarcinoma 755, mammary carcinoma
YMC, reticulum cell sarcoma A-RCS, lymphoma
P1798, and osteosarcoma 124F. It was, however,
ineffective in ascites, leukemias, plasma cell tumors, or
Ehrlich carcinoma. In phase II evaluation studies, gallium
nitrate has shown antitumor activity in patients with either
refractory lymphomas or small-cell lung carcinomas or
bladder cancer, with total objective response rates of 28%
and 11%, respectively. This drug has displayed its strongest
antineoplastic activity in the treatment of non-Hodgkin’s
lymphoma and bladder cancer.
In addition, according to two phase III comparative
trials,thanks to an inhibitory effect on calcium reabsorption
from bone, gallium nitrate is superior to alternative
therapies in the treatment of hypercalcemia associated with
malignancy and related disease states. Based on its clinical
efficacy, gallium nitrate (Ganite ) was approved by the Food
and Drug Administration (FDA) for the treatment of cancerassociated
hypercalcemia.Apart from its ability to control hypercalcemia, gallium
nitrate has been shown to inhibit bone turnover and
decrease osteolysis in patients with multiple myeloma
and in patients with bone metastases from a variety of
different cancers. Gallium(III) nitrate solution, is used as the material for producing gallium salts and for scientific research and chemical reagent. It is also used as an intermediate. Regulator (calcium).
